Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hepatocellular carcinoma larger than 3 cm and non-resectable, with a diagnosis established either by:~  * dynamic imaging (non-invasively), showing a typical contrast enhancement and wash-out~ * histopathology~* satellite lesions are allowed (at most three lesions) as long as the doses constraints are still achievable~* Hepatocellular carcinoma belonging to Barcelona Clinic Liver Cancer Stage System class B~* Tumor must be measurable on a multi-phase MRI according to mRECIST criteria~* Non-tumoral liver volume ≥ 800 cc~* Child-Pugh (CP) A to B7 cirrhosis~* HCC Patients can be included if they require treatment prior to liver transplantation~* ECOG performance status 0-1~* AST/ALT \< 5 times ULN~* Initial platelets ≥ 50 000 x 10E9/l, neutrophils \> 1500 x 10E9/l, Hb \> 9 g/dl~* Serum creatinine \< 1.5 X normal, or calculated Creatinine clearance rate ≥ 60 mL/min~* As tumor biopsy can be performed after inclusion, pure hepatocellular carcinoma but also mixed hepatocellular carcinoma will be allowed in this trial. Cholangiocarcinoma cannot be included.~* Written informed consent form to be signed,~* Patient willing and able to comply to the follow-up schedule~* Patients in fertile age should use a contraceptive method during treatment and 4 months after.~Exclusion Criteria:~* Eligibility for resection or ablative treatments~* Extra hepatic spread of the disease~* Previous treatment of the same lesion with TACE~* Previous treatment with selective internal radiotherapy or radiotherapy to the upper abdomen~* Uncontrolled Ascites~* Uncontrolled Encephalopathy~* Any clinical sign of acute viral or non-viral hepatitis (new serological testing are not required)~* Known current pregnancy~* Uncontrolled active co-morbidity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trans-Arterial Chemo-embolization (TACE) (Type: ACTIVE_COMPARATOR): Trans-arterial Embolisation will be performed with drug-eluting beads loaded with Doxorubicin. First session will be given within 4 weeks after randomization.~4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.~Once complete response is achieved, the follow-up period will start. The date of the last session of TACE corresponds to the treatment completion date.
- TACE+Stereotactic Ablative Radiotherapy (Type: EXPERIMENTAL): The first part of the treatment, which is the DEB-TACE delivery, will be exactly the same than in arm A. The radiotherapy (SABR) will then start within 4 to 6 weeks after.~Afterwards, 4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.~Once complete response is achieved, the follow-up period will start. The date of the last SABR fraction or the last session of TACE corresponds to the treatment completion date.

Based on this trial design, predict the completion outcome and termination type (if applicable).